Literature DB >> 11313868

Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression.

S H Park1, Y S Kim, B K Park, S Hougaard, S J Kim.   

Abstract

Transcriptional repression of the TGF-beta type II receptor (RII) is one of the mechanisms leading to TGF-beta resistance. The newly identified epithelium-specific ets transcription factor ERT/ESX/ELF-3/ESE-1/jen binds to the TGF-beta RII promoter and induces promoter activity. The human gastric cancer cell lines, which show undetectable level of TGF-beta RII mRNA, do not express ERT mRNA. To study the molecular mechanisms of loss of ERT expression, we have cloned and characterized the human ERT promoter. DNA transfection experiments and electrophoretic mobility shift assays have revealed the existence of a distinct enhancer element (-186 to -177) which we named ESE (ERT promoter specific element). Deletion of the ESE markedly decreased expression of the target gene. ESE interacts with two distinct nuclear protein complexes, at least one of which appears to be inactivated in a cell line which does not express the ERT mRNA, compared to a cell line expressing the ERT mRNA. These results suggest the possibility that inactivation of the sequence-specific DNA binding protein to the region from -186 to -177 contributes to the loss of ERT expression, leading to the loss of TGF-beta type II receptor mRNA in human gastric cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313868     DOI: 10.1038/sj.onc.1204227

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

Review 1.  Moonlighting proteins in cancer.

Authors:  Kyung-Won Min; Seong-Ho Lee; Seung Joon Baek
Journal:  Cancer Lett       Date:  2015-10-20       Impact factor: 8.679

2.  Transcriptome profiling of cancer tissues in Chinese patients with gastric cancer by high-throughput sequencing.

Authors:  Peiying Tian; Chunli Liang
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

3.  Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy.

Authors:  Akiko Sakurai; Hiroyuki Ono; Arisa Ochi; Motokazu Matsuura; Sakiya Yoshimoto; Seiji Kishi; Taichi Murakami; Tatsuya Tominaga; Kojiro Nagai; Hideharu Abe; Toshio Doi
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

4.  Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.

Authors:  Kai Wang; Siu Tsan Yuen; Jiangchun Xu; Siu Po Lee; Helen H N Yan; Stephanie T Shi; Hoi Cheong Siu; Shibing Deng; Kent Man Chu; Simon Law; Kok Hoe Chan; Annie S Y Chan; Wai Yin Tsui; Siu Lun Ho; Anthony K W Chan; Jonathan L K Man; Valentina Foglizzo; Man Kin Ng; April S Chan; Yick Pang Ching; Grace H W Cheng; Tao Xie; Julio Fernandez; Vivian S W Li; Hans Clevers; Paul A Rejto; Mao Mao; Suet Yi Leung
Journal:  Nat Genet       Date:  2014-05-11       Impact factor: 38.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.